Diversity of variant alleles encoding Kidd, Duffy, and Kell antigens in individuals with sickle cell disease using whole genome sequencing data from the NHLBI TOPMed Program.


Journal

Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360

Informations de publication

Date de publication:
02 2021
Historique:
received: 04 06 2020
revised: 17 08 2020
accepted: 18 10 2020
pubmed: 25 11 2020
medline: 9 7 2021
entrez: 24 11 2020
Statut: ppublish

Résumé

Genetic variants in the SLC14A1, ACKR1, and KEL genes, which encode Kidd, Duffy, and Kell red blood cell antigens, respectively, may result in weakened expression of antigens or a null phenotype. These variants are of particular interest to individuals with sickle cell disease (SCD), who frequently undergo chronic transfusion therapy with antigen-matched units. The goal was to describe the diversity and the frequency of variants in SLC14A1, ACKR1, and KEL genes among individuals with SCD using whole genome sequencing (WGS) data. Two large SCD cohorts were studied: the Recipient Epidemiology and Donor Evaluation Study III (REDS-III) (n = 2634) and the Outcome Modifying Gene in SCD (OMG) (n = 640). Most of the studied individuals were of mixed origin. WGS was performed as part of the National Heart, Lung, and Blood Institute's Trans-Omics for Precision Medicine (TOPMed) program. In SLC14A1, variants included four encoding a weak Jk We described the diversity and distribution of SLC14A1, ACKR1, and KEL variants in two large SCD cohorts, comprising mostly individuals of mixed ancestry. This information may be useful for planning the transfusion support of patients with SCD.

Sections du résumé

BACKGROUND
Genetic variants in the SLC14A1, ACKR1, and KEL genes, which encode Kidd, Duffy, and Kell red blood cell antigens, respectively, may result in weakened expression of antigens or a null phenotype. These variants are of particular interest to individuals with sickle cell disease (SCD), who frequently undergo chronic transfusion therapy with antigen-matched units. The goal was to describe the diversity and the frequency of variants in SLC14A1, ACKR1, and KEL genes among individuals with SCD using whole genome sequencing (WGS) data.
STUDY DESIGN AND METHODS
Two large SCD cohorts were studied: the Recipient Epidemiology and Donor Evaluation Study III (REDS-III) (n = 2634) and the Outcome Modifying Gene in SCD (OMG) (n = 640). Most of the studied individuals were of mixed origin. WGS was performed as part of the National Heart, Lung, and Blood Institute's Trans-Omics for Precision Medicine (TOPMed) program.
RESULTS
In SLC14A1, variants included four encoding a weak Jk
CONCLUSIONS
We described the diversity and distribution of SLC14A1, ACKR1, and KEL variants in two large SCD cohorts, comprising mostly individuals of mixed ancestry. This information may be useful for planning the transfusion support of patients with SCD.

Identifiants

pubmed: 33231305
doi: 10.1111/trf.16204
doi:

Substances chimiques

ACKR1 protein, human 0
Duffy Blood-Group System 0
Kell Blood-Group System 0
Kidd Blood-Group System 0
Membrane Glycoproteins 0
Membrane Transport Proteins 0
Receptors, Cell Surface 0
KEL protein, human EC 3.4.24.-
Metalloendopeptidases EC 3.4.24.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

603-616

Informations de copyright

© 2020 AABB.

Références

Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The cooperative study of sickle cell disease. Blood. 1990;76:1431-1437.
Dezan MR, Oliveira VB, Bianchi JV, et al. Effectiveness of a red cell antigen-matching transfusion protocol in sickle cell disease patients. ISBT Sci Ser. 2016;11:132-139.
Hendrickson JE, Hod EA, Perry JR, et al. Alloimmunization to transfused HOD red blood cells is not increased in mice with sickle cell disease. Transfusion. 2012;52:231-240.
Pirenne F, Bartolucci P, Habibi A. Management of delayed hemolytic transfusion reaction in sickle cell disease: prevention, diagnosis, treatment. Transfus Clin Biol. 2017;24:227-231.
Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion. 2001;41:1086-1092.
Lasalle-Williams M, Nuss R, Le T, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion. 2011;51:1732-1739.
Van Buren NL, Gorlin JB, Corby SM, et al. How do I incorporate red cell genotyping to improve chronic transfusion therapy? Transfusion. 2020;60:16-25.
Casas J, Friedman DF, Jackson T, Vege S, Westhoff CM, Chou ST. Changing practice: red blood cell typing by molecular methods for patients with sickle cell disease. Transfusion. 2015;55:1388-1393.
Reid ME, Halter Hipsky C, Hue-Roye K, Hoppe C. Genomic analyses of RH alleles to improve transfusion therapy in patients with sickle cell disease. Blood Cells Mol Dis. 2014;52:195-202.
Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013;122:1062-1071.
Dinardo CL, Kelly S, Dezan MR, et al. Diversity of RH and transfusion support in Brazilian sickle cell disease patients with unexplained Rh antibodies. Transfusion. 2019;59:3228-3235.
Billingsley KL, Posadas JB, Moulds JM, Gaur LK. A novel JK null allele associated with typing discrepancies among African Americans. Immunohematology. 2013;29:145-148.
Burgos A, Vege S, Velliquette R, Lomas-Francis C, Westhoff C. Serologic and molecular investigation of novel Kidd system alleles in African-Americans (abstract). Transfusion. 2013;53:39A-40A.
Horn T, Castilho L, Moulds JM, et al. A novel JKA allele, nt561C>A, associated with silencing of Kidd expression. Transfusion. 2012;52:1092-1096.
Kormoczi GF, Wagner T, Jungbauer C, et al. Genetic diversity of KELnull and KELel: a nationwide Austrian survey. Transfusion. 2007;47:703-714.
Lee S. Molecular basis of Kell blood group phenotypes. Vox Sang. 1997;73:1-11.
Moulds JM, Persa R, Rierson D, et al. Three novel alleles in the Kell blood group system resulting in the Knull phenotype and the first in a Native American. Transfusion. 2013;53:2867-2871.
Perez I, Castilho L, Goytendia A, et al. First report of a KELnull phenotype in Peru and a lesson of invisible genetic disparity. Transfus Apher Sci. 2019;58:453-456.
Yazdanbakhsh K, Rios M, Storry JR, et al. Molecular mechanisms that lead to reduced expression of Duffy antigens. Transfusion. 2000;40:310-320.
Moller M, Joud M, Storry JR, Olsson ML. Erythrogene: a database for in-depth analysis of the extensive variation in 36 blood group systems in the 1000 Genomes Project. Blood Adv. 2016;1:240-249.
Guelsin GA, Sell AM, Castilho L, et al. Benefits of blood group genotyping in multi-transfused patients from the south of Brazil. J Clin Lab Anal. 2010;24:311-316.
Pellegrino J Jr, Castilho L, Rios M, De Souza CA. Blood group genotyping in a population of highly diverse ancestry. J Clin Lab Anal. 2001;15:8-13.
Stabentheiner S, Danzer M, Niklas N, et al. Overcoming methodical limits of standard RHD genotyping by next-generation sequencing. Vox Sang. 2011;100:381-388.
Fichou Y, Audrezet MP, Gueguen P, Le Marechal C, Ferec C. Next-generation sequencing is a credible strategy for blood group genotyping. Br J Haematol. 2014;167:554-562.
Giollo M, Minervini G, Scalzotto M, Leonardi E, Ferrari C, Tosatto SC. BOOGIE: predicting blood groups from high throughput sequencing data. PLoS One. 2015;10:e0124579.
Fichou Y, Mariez M, Le Marechal C, Ferec C. The experience of extended blood group genotyping by next-generation sequencing (NGS): Investigation of patients with sickle-cell disease. Vox Sang. 2016;111:418-424.
Lane WJ, Westhoff CM, Uy JM, et al. Comprehensive red blood cell and platelet antigen prediction from whole genome sequencing: proof of principle. Transfusion. 2016;56:743-754.
Chou ST, Flanagan JM, Vege S, et al. Whole-exome sequencing for RH genotyping and alloimmunization risk in children with sickle cell anemia. Blood Adv. 2017;1:1414-1422.
Dezan MR, Ribeiro IH, Oliveira VB, et al. RHD and RHCE genotyping by next-generation sequencing is an effective strategy to identify molecular variants within sickle cell disease patients. Blood Cells Mol Dis. 2017;65:8-15.
Wheeler MM, Lannert KW, Huston H, et al. Genomic characterization of the RH locus detects complex and novel structural variation in multi-ethnic cohorts. Genet Med. 2019;21:477-486.
Lane WJ, Vege S, Mah HH, et al. Automated typing of red blood cell and platelet antigens from whole exome sequences. Transfusion. 2019;59:3253-3263.
Carneiro-Proietti ABF, Kelly S, Miranda Teixeira C, et al. Clinical and genetic ancestry profile of a large multi-centre sickle cell disease cohort in Brazil. Br J Haematol. 2018;182:895-908.
Elmariah H, Garrett ME, De Castro LM, et al. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol. 2014;89:530-535.
Lemes RB, Nunes K, Carnavalli JEP, et al. Inbreeding estimates in human populations: applying new approaches to an admixed Brazilian isolate. PLoS One. 2018;13:e0196360.
Xu JZ, Garrett ME, Soldano KL, et al. Clinical and metabolomic risk factors associated with rapid renal function decline in sickle cell disease. Am J Hematol. 2018;93:1451-1460.
Guo Z, Wang C, Yan K, et al. The mutation spectrum of the JK-null phenotype in the Chinese population. Transfusion. 2013;53:545-553.
Hamilton JR. Kidd blood group system: a review. Immunohematology. 2015;31:29-35.
Wester ES, Storry JR, Olsson ML. Characterization of Jk(a+(weak)): a new blood group phenotype associated with an altered JK*01 allele. Transfusion. 2011;51:380-392.
Olsson ML, Smythe JS, Hansson C, et al. The Fy(x) phenotype is associated with a missense mutation in the Fy(b) allele predicting Arg89Cys in the Duffy glycoprotein. Br J Haematol. 1998;103:1184-1191.
Fichou Y, Berlivet I, Richard G, Tournamille C, Castilho L, Ferec C. Defining blood group gene reference alleles by long-read sequencing: proof of concept in the ACKR1 gene encoding the Duffy antigens. Transfus Med Hemother. 2020;47:23-32.
Zimmerman PA, Woolley I, Masinde GL, et al. Emergence of FY*A(null) in a Plasmodium vivax-endemic region of Papua New Guinea. Proc Natl Acad Sci U S A. 1999;96:13973-13977.
Kempinska-Podhorodecka A, Knap O, Drozd A, et al. Analysis for genotyping Duffy blood group in inhabitants of Sudan, the fourth cataract of the Nile. Malar J. 2012;11:115.
Hoher G, Fiegenbaum M, Almeida S. Molecular basis of the Duffy blood group system. Blood Transfus. 2018;16:93-100.
Tournamille C, Le Van Kim C, Gane P, et al. Arg89Cys substitution results in very low membrane expression of the Duffy antigen/receptor for chemokines in Fy(x) individuals. Blood. 1998;92:2147-2156.
Castilho L, Rios M, Pellegrino J Jr, Saad ST, Costa FF, Reid ME. A novel FY allele in Brazilians. Vox Sang. 2004;87:190-195.
Schmid P, Ravenell KR, Sheldon SL, Flegel WA. DARC alleles and Duffy phenotypes in African Americans. Transfusion. 2012;52:1260-1267.
Lee S, Russo DC, Reiner AP, et al. Molecular defects underlying the Kell null phenotype. J Biol Chem. 2001;276:27281-27289.
Boturao-Neto E, Yamamoto M, Chiba AK, et al. Molecular basis of KELnull phenotype in Brazilians. Transfus Med Hemother. 2015;42:52-58.
Arnoni CP, Gazito D, Muniz JG, et al. Two novel KEL alleles encoding K0 phenotypes in Brazilians. Transfusion. 2014;54:2128-2129.
Brunetta D, Carlos LM, Costa TB, et al. A novel KEL silencing allele in a Brazilian patient with anti-Ku. Transfusion. 2017;57:487-488.

Auteurs

Carla L Dinardo (CL)

Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, Brazil.
Institute of Tropical Medicine, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

Theo G M Oliveira (TGM)

Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, Brazil.

Shannon Kelly (S)

Vitalant Research Institute, San Francisco, California, USA.

Allison Ashley-Koch (A)

Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.

Marilyn Telen (M)

Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.

Luciana C Schmidt (LC)

Fundação HEMOMINAS, Belo Horizonte, Brazil.

Shirley Castilho (S)

HEMORIO, Rio de Janeiro, Brazil.

Karla Melo (K)

Fundação HEMOPE, Recife, Brazil.

Marcia R Dezan (MR)

Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, Brazil.

Marsha M Wheeler (MM)

Department of Genome Sciences, School of Medicine, University of Washington, Seattle, Washington, USA.

Jill M Johnsen (JM)

University of Washington, Seattle, Washington, USA.
Bloodworks, Research Institute, Seattle, USA.

Deborah A Nickerson (DA)

Department of Genome Sciences, School of Medicine, University of Washington, Seattle, Washington, USA.

Deepti Jain (D)

University of Washington, Seattle, Washington, USA.

Brian Custer (B)

Vitalant Research Institute, San Francisco, California, USA.

Alexandre C Pereira (AC)

Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), São Paulo, Brazil.

Ester C Sabino (EC)

Institute of Tropical Medicine, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH